[go: up one dir, main page]

MY113489A - Reversible protease inhibitors - Google Patents

Reversible protease inhibitors

Info

Publication number
MY113489A
MY113489A MYPI96001076A MYPI19961076A MY113489A MY 113489 A MY113489 A MY 113489A MY PI96001076 A MYPI96001076 A MY PI96001076A MY PI19961076 A MYPI19961076 A MY PI19961076A MY 113489 A MY113489 A MY 113489A
Authority
MY
Malaysia
Prior art keywords
protease inhibitors
reversible protease
reversible
inhibitors
specific
Prior art date
Application number
MYPI96001076A
Inventor
Lee Klaus Jeffrey
T Palmer James
Rasnick David
Original Assignee
Arris Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharm Corp filed Critical Arris Pharm Corp
Publication of MY113489A publication Critical patent/MY113489A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

THE INVENTION RELATES TO NOVEL REVERSIBLE PROTEASE. THE INHIBITORS ARE SPECIFIC TO CYSTEINE PROTEASES.
MYPI96001076A 1995-03-24 1996-03-22 Reversible protease inhibitors MY113489A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40999695A 1995-03-24 1995-03-24

Publications (1)

Publication Number Publication Date
MY113489A true MY113489A (en) 2002-03-30

Family

ID=23622800

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI96001076A MY113489A (en) 1995-03-24 1996-03-22 Reversible protease inhibitors

Country Status (15)

Country Link
EP (1) EP0817778A1 (en)
JP (1) JPH11503417A (en)
KR (1) KR19980703261A (en)
CN (1) CN1071751C (en)
AU (1) AU713492B2 (en)
CA (1) CA2216151A1 (en)
CZ (1) CZ298197A3 (en)
IL (1) IL117638A0 (en)
MY (1) MY113489A (en)
NO (1) NO311573B1 (en)
NZ (1) NZ305626A (en)
PL (1) PL322409A1 (en)
TW (1) TW470750B (en)
WO (1) WO1996030353A1 (en)
ZA (1) ZA962336B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE255126T1 (en) 1996-04-22 2003-12-15 Massachusetts Inst Technology SUPPRESSION OF IMMUNE RESPONSE BY INHIBITING CATHEPSIN S
AU733621B2 (en) * 1996-07-30 2001-05-17 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating diseases associated with tryptase activity
DE19817461A1 (en) 1998-04-20 1999-10-21 Basf Ag New benzamide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc.
JP2002538151A (en) 1999-03-02 2002-11-12 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Compounds useful as reversible inhibitors of cathepsin
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
BR0013966A (en) * 1999-09-13 2004-06-15 Boehringer Ingelheim Pharma Spiroeterocyclic compounds useful as reversible inhibitors of cysteine proteases
WO2001036604A2 (en) 1999-11-18 2001-05-25 Corvas International, Inc. Nucleic acids encoding endotheliases, endotheliases and uses thereof
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US7309703B2 (en) 2000-08-14 2007-12-18 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
CA2419550A1 (en) 2000-08-14 2002-02-21 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazoles
CZ307185B6 (en) 2000-08-14 2018-03-07 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazole, a pharmaceutical composition containing it and their medical applications
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
RU2290179C2 (en) 2000-09-06 2006-12-27 Орто-Макнейл Фармасьютикал, Инк. Method for treatment of allergy by using substituted pyrazoles
US20020107266A1 (en) * 2000-12-12 2002-08-08 Marguerita Lim-Wilby Compounds, compositions and methods for treatment of parasitic infections
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
IL156577A0 (en) 2000-12-22 2004-01-04 Axys Pharm Inc Selective cathepsin s inhibitors and pharmaceutical compositions containing the same
CA2460125A1 (en) * 2001-09-14 2003-03-27 Aventis Pharmaceuticals Inc. Novel compounds and compositions as cathepsin inhibitors
US6900237B2 (en) 2001-09-14 2005-05-31 Axys Pharmaceuticals, Inc. Sulfonamide compounds as protease inhibitors
JP2005514353A (en) 2001-11-14 2005-05-19 アベンティス・ファーマスーティカルズ・インコーポレイテツド Oligopeptides as cathepsin S inhibitors and compositions containing them
GB0311406D0 (en) * 2003-05-17 2003-06-25 Queen Mary & Westfield College Substituted phosphonate fluorescent sensors,and use thereof
JP2011524340A (en) * 2008-05-21 2011-09-01 ニュー・ワールド・ラボラトリーズ・インコーポレイテッド Selective caspase inhibitors and uses thereof
US9045524B2 (en) 2009-05-21 2015-06-02 Novagenesis Foundation Selective caspase inhibitors and uses thereof
WO2011069149A2 (en) 2009-12-04 2011-06-09 Dcb-Usa Llc Cathepsin s inhibitors
CA2833082C (en) 2011-04-15 2019-12-31 New World Laboratories, Inc. Selective cysteine protease inhibitors and uses thereof
KR101309578B1 (en) * 2011-05-06 2013-09-17 연세대학교 산학협력단 Dityrosine compounds having selectivity for cysteine proteases and method for monitoring cysteine proteases using the same
KR101385855B1 (en) * 2012-10-16 2014-04-22 이동익 Diaromatic amino acid-based substrate for detecting cathepsins
US20200361967A1 (en) * 2018-01-19 2020-11-19 Osaka Soda Co., Ltd. Organosilicon compound and rubber composition comprising the same
EP3553521A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Gingivitis diagnostic methods, uses and kits

Also Published As

Publication number Publication date
ZA962336B (en) 1996-07-31
CZ298197A3 (en) 1998-03-18
AU5367496A (en) 1996-10-16
NZ305626A (en) 2000-01-28
JPH11503417A (en) 1999-03-26
EP0817778A1 (en) 1998-01-14
AU713492B2 (en) 1999-12-02
NO974403D0 (en) 1997-09-23
CA2216151A1 (en) 1996-10-03
CN1071751C (en) 2001-09-26
TW470750B (en) 2002-01-01
NO974403L (en) 1997-11-17
IL117638A0 (en) 1996-07-23
WO1996030353A1 (en) 1996-10-03
KR19980703261A (en) 1998-10-15
NO311573B1 (en) 2001-12-10
CN1184472A (en) 1998-06-10
PL322409A1 (en) 1998-01-19

Similar Documents

Publication Publication Date Title
MY113489A (en) Reversible protease inhibitors
IL112759A0 (en) Novel cysteine protease inhibitors
ZA964751B (en) Reversible cysteine protease inhibitors
AU5122196A (en) Cysteine protease inhibitor
PL331533A1 (en) Cysteine protease inhibitors
ZA992447B (en) Quinoxalinones as serine protease inhibitors.
NO981938D0 (en) protease inhibitors
AU1266495A (en) Cysteine protease inhibitors containing heterocyclic leaving groups
AU4236796A (en) Cysteine protease and serine protease inhibitors
AU8875398A (en) 1-amino-7-isoquinoline derivatives as serine protease inhibitors
BG104885A (en) Novel heterocyclically substituted amides with cysteine protease-inhibiting effect
HUP9901187A3 (en) Serine protease inhibitors
EP0975353A4 (en) Peptidyl-2-amino-1-hydroxyalkanesulfonic acid cysteine protease inhibitors
ZA971733B (en) Serine protease inhibitors.
HK1016495A1 (en) Phosphorous-containing cysteine and serine protease inhibitors
EP0923535A4 (en) Inhibitors of cysteine protease
HK1029936A1 (en) Quinoline-containing alpha-ketoamide cysteine and serine protease inhibitors
ZA971667B (en) Serine protease inhibitors.
IL139187A0 (en) Cysteine protease inhibitors
IL123771A0 (en) Metal complexes as cysteine protease inhibitors
NO975534D0 (en) Imidazo- £ 1.5µ-pyridine-derived serine protease inhibitors
AU1730797A (en) 3-substituted-4-oxa-1-azabicyclo{3,2,0}heptan-7-one as cysteine protease inhibitors
ATE311440T1 (en) BACILLUS PROTEASES
ZA969078B (en) Inhibitors of cysteine protease.
ATE313624T1 (en) BACILLUS PROTEASES